Heat Biologics (Nasdaq: HTBX) has initiated dosing in its Phase 2 trial of Viagenpumatucel-L (HS-110) in patients with non-small cell ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE